12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
0936
THE DIFFERENCES OF PROTEIN EXPRESSION BETWEEN CML-CP AND CML-BC
BY COMPARATIVE PROTEOME ANALYSIS
X. Liu
Nanfang Hospital, GUANGZHOU, China
Background. The clinical course of chronic myeloid leukemia (CML) is
characteristically triphasic, comprising chronic and accelerated phases
and blast crisis. Chronic phase (CP) is characterized by the Ph chromosome
as the sole genetic abnormality and blast crisis (BC), which is the
terminal phase of CML, often associated with additional chromosomal
and molecular secondary changes. Although CML is probably the most
extensively studied human malignancy, the mechanisms of CML blast
crisis are still poorly understood. Aims. The aims of current study are to
screen and identify CML-BC related proteins and explore the mechanism
of CML-BC. Methods. The changes of protein expression between
CML-CP (25 cases) and CML-BC (20 cases) were analyzed by Twodimensional
polyacrylamide gel electrophoresis (2-D PAGE), and the
proteins were identified by peptide mass fingerprint in combination
with database searching. Results. Compared with that of CML-CP, 33
proteins’ intensities of CML-BC were found to have significant difference
including 23 increasing intensity and 13 decreasing. 15 proteins
were identified including proteasome activator complex, heterogeneous
nuclear ribonucleoprotein, annexin A4, serine proteinase inhibitor,
annexin A1, glyceradehyde-3-phosphate dehydrogenase, RhoGDI, enolase,
proteasome subunit 6a, GTP binding protein, leukotriene A4 hydrolase,
Rac-RhoGDI, thioredoxin, proteasome subunit 4‚ and DJ-1 protein,
and the functions of these proteins involve cell signal transduction,
apoptosis, proliferation and transcription. Conclusions. Our study provided
a profile of protein expression difference between CML-CP and
CML-BC and contributed to understand the mechanisms of CML blast
crisis.
0937
FACTOR V LEIDEN AND G20210A PROTHROMBIN MUTATIONS IN PATIENT
WITH RECURRENT PREGNANCY LOSS: DATA FROM SOUTHEAST OF TURKEY
A. Altintas, S. Pasa, O. Ayyildiz, T. Cil
Dicle University Medical Faculty, DIYARBAKIR, Turkey
Background and Aim. The pathophysiology of pregnancy loss is complex
and poorly understood. Historically, the causes of recurrent pregnancy
loss (RPL) have been classified as genetic, infective, anatomical,
endocrine, immune and idiopathic. However, even after detailed investigation,
as many as 80% of all cases remain unexplained. Based on the
histologic findings of extensive infarction and necrosis in the placentas
of women with antiphospholipid syndrome, researchers postulate that
utero-placental thrombosis may lead to placental infarction and eventual
fetal death. Therefore, within the past 10 years interest in associations
between thrombophilia and RPL has increased remarkably. Actually,
thrombophilias have been included in the causes of RPL. In the recent
years various studies have examined the incidence of genetic prothrombotic
mutation in women with unexplained pregnancy loss. Some of
these studies confirmed an association between thrombophilic gene
mutations and recurrent miscarriage but other studies detected no association.
We performed a case-control study because of the conflicting
results of studies and in view of lack of data on Southeast of Turkey population.
Moreover, we know that there may be major racial variation in
gene polymorphisms. The aim of this case-control study was to investigate
the prevalence of FV-Leiden and FII G20210A mutations, and their
impact on the development of early recurrent miscarriage in patients
with history of unexplained early fetal loss on Southeast of Turkey population.
Methods. This case-control study was performed in 114 women
out of 403 patients with a history of two or more consecutive spontaneous
abortions of unexplained etiology during the first trimester. The
control group consisted of 185 age-matched women without previous
miscarriage or pregnancy complications. Factor V Leiden and FII
G20210A were studied with LightCycler PCR. Results. In this series of
114 patients, 11 cases (9.6%) were found to have hereditary thrombophilia,
and this prevalence was not higher than that found in the control
group. In addition, in the group of patient with RPL we found higher
prevalence of both genetic prothrombotic mutation in comparison
with controls. However, these prevalences did not reach statistical significance
in comparison with controls. Conclusion. The most common
causes of hereditary thrombophilia (FV-Leiden and FII G20210A) was
not found to be associated with first trimester recurrent pregnancy loss.
350 | haematologica/the hematology journal | 2007; 92(s1)
0938
RAPID INFUSION OF RITUXIMAB OVER 90-MINUTES FROM SECOND INFUSION
ONWARDS ON AN OUT-PATIENT BASIS IS SAFE AND IMPROVES RESOURCE UTILIZATION
K. Ramadan, 1 C. McCoy, 2 Y.-L. Ong, 2 A.-H. Eswedi, 2 M.R. El-Agnaf2 1 2 St. Pual's Hospiatl, VANCOUVER, Canada; Ulster Hospital, BELFAST,
United Kingdom
Background. Administration of rituximab can be associated with substantial
infusion-related toxicity, including allergic/hypersensitivity reactions
and rarely a fatal cytokine release syndrome. These adverse reactions
(AR) are more commonly seen with first infusion (risk of grade ≥3
is 7%) compared with subsequent infusions where the risk of grade ≥3
infusion reactions is 2%. To minimize the risk of AR, rituximab has
been traditionally infused over prolonged period of time (average 5-6 h
for first infusion and 3-4 h for subsequent infusions). With ever increasing
indications for rituximab therapy, day therapy units are expected to
accommodate more patients. Aims. The aim of this study is to assess the
safety of rapid rituximab infusion (over 90 minutes) and to evaluate the
impact of this strategy on resource utilization in day therapy units. Methods.
This is a prospective, single institution study started in April 2005
for one year at the Ulster hospital, Northern Ireland. Eligibility criteria
included patients with CD20 + NHL and meet one of the current indications
for rituximab therapy, age >16, all patients had received previous
treatment with a first infusion of rituximab according to drug monograph
and did not develop grades ≥3 infusion related syndrome or
cytokine release syndrome, no bulky disease (disease mass